Seer, Inc. ( (SEER) ) has released its Q1 earnings. Here is a breakdown of the information Seer, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Seer, Inc., a life sciences company specializing in proteomics, has reported its financial results for the first quarter of 2025, highlighting its innovative Proteograph Product Suite. The company achieved a revenue of $4.2 million, marking a 37% increase compared to the same period last year, driven by higher product sales and service revenue. A significant contract for a 10,000-sample study with Discovery Life Sciences was also secured, showcasing the growing demand for Seer’s technology.
The company’s gross profit for the quarter was $2.1 million, with a gross margin of 49%. Despite a net loss of $19.9 million, Seer managed to reduce its operating expenses by 14% from the previous year, primarily due to decreased stock-based compensation and laboratory expenses. The company ended the quarter with $285 million in cash, cash equivalents, and investments, indicating a strong financial position.
Seer’s strategic focus on expanding the validation of its platform through customer publications and collaborations has been a key driver of its recent success. The company shipped as many Proteograph instruments in the first quarter of 2025 as it did throughout 2024, reflecting the increasing adoption of its technology. Furthermore, Seer continues to anticipate full-year revenue growth of 24% over 2024, with expectations set between $17 million and $18 million.
Looking ahead, Seer remains optimistic about its long-term vision despite the ongoing macroeconomic challenges. The management’s commitment to enabling deep, unbiased proteomics at a population scale is expected to continue driving the company’s growth and innovation in the life sciences sector.